Bio-Rad Laboratories, Inc.  

(Public, NYSE:BIO.B)   Watch this stock  
Find more results for BIO.B
0.00 (0.00%)
Feb 1 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 117.35 - 151.22
Open     -
Vol / Avg. 6.00/79.00
Mkt cap 3.69B
P/E 36.27
Div/yield     -
EPS 3.50
Shares 5.13M
Beta 1.10
Inst. own 367%
Apr 27, 2016
Bio Rad Laboratories Inc Annual Shareholders Meeting (Estimated) - 7:00PM EDT - Add to calendar
Feb 25, 2016
Q4 2015 Bio Rad Laboratories Inc Earnings Call - 5:00PM EST - Add to calendar
Feb 25, 2016
Q4 2015 Bio Rad Laboratories Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 10, 2016
Bio Rad Laboratories Inc at Leerink Partners Global Healthcare Conference - 3:30PM EST - Add to calendar
Jan 13, 2016
Bio Rad Laboratories Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 3.70% 4.08%
Operating margin 6.95% 6.88%
EBITD margin - 13.79%
Return on average assets 1.94% 2.64%
Return on average equity 2.91% 4.06%
Employees 7,600 -
CDP Score - -


United States - Map
+1-510-7247000 (Phone)
+1-510-7415815 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies products and systems used for the life science research, healthcare, analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials, and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, manufactures and markets a range of over 5,000 reagents, apparatus and laboratory instruments. The Company’s Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rad’s product brands include Droplet Digital and BioPlex. As of December 31, 2014, the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.

Officers and directors

Norman D Schwartz Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Christine A Tsingos Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
John P. Goetz Chief Operating Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Shawn M. Soderberg Executive Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Michael Crowley Executive Vice President, Global Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Shannon Hall Executive Vice President, President, Life Science Group
Age: 45
Bio & Compensation  - Reuters
John Hertia Executive Vice President, President, Clinical Diagnostics Group
Age: 59
Bio & Compensation  - Reuters
Giovanni Magni Executive Vice President, Chief Strategy Officer
Age: 58
Bio & Compensation  - Reuters
Ronald W. Hutton Vice President, Treasurer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Alice N. Schwartz Director
Age: 88
Bio & Compensation  - Reuters